Press Room

RDD Europe 2015

Start
Tuesday, May 05, 2015 - 00:00
End
Friday, May 08, 2015 - 00:00
Location: Nice, France
Booth Number: Table nr. 32

RDD Europe 2015 will be held from Tuesday 5th May until Friday 8th May 2015 at the Palais des Congres d'Antibes, Nice, France. Hovione will be present with a table (nr. 32), a presentation, a workshop and a set of posters.

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at RDD.

contact us button | Hovione

 

HOVIONE'S PRESENTATION
Optimized Composite Particles for API-independent Formulations with Enhanced Performance

Speaker: Eunice Costa, PhD (Scientist, Drug Product Development)
Date: Friday, May 5, 2015
Time: 8:30 AM

HOVIONE'S WORKSHOP
Trends in Inhalation Drug Development: Particle Engineering and Formulation Strategies

Speakers: Eunice Costa, PhD (Scientist, Drug Product Development)
                  Filipe Neves, PhD (Senior Scientist, Group Leader, Drug Product Development)
Date: Wednesday, May 6, 2015 
Time: tbd - afternoon from 2:00 to 6:00 PM

  • Introduction: This workshop addresses trends in particle engineering (PE) technologies, and formulation strategies to overcome problems during the development of inhalation drugs. Participants will gain insight into innovative approaches via comprehensive and diverse case studies chosen to illustrate the complexity of manufacturing processes. 
     
  • Workshop Content: Participants will learn the fundamentals of inhalation delivery, together with an overview of market trends and basic concepts associated with metered dose inhalation (MDI) and dry powder inhalation (DPI); for the latter platform, carrier based and composite particles based approaches will be emphasized. The impact of different particle engineering technologies on the final performance of both MDI and DPI (carrier based) products will be discussed. Case studies will link API properties (measured by cutting edge techniques) and formulation strategy, with the overall success of a given delivery platform. Lastly, DPI formulation based on spray dried composite particle approaches will be explored using case studies covering formulation development and process scale-up.
     
  • Outcome for Participants: The participants will gain insight into several innovative approaches, including a number of comprehensive and diverse case studies, which will illustrate the complex relationships linking inhaler design to particle engineering and formulation strategies.
     

POSTERS

Impact of the Size-Reduction Technology on the Performance of Suspension Pressurized Metered Dosed Inhalers: Benchmarking with Dry Powder Inhalers
Eunice Costa

Performance Optimization in Early DPI Development: Enabling High Dosage Drug Delivery to the Lungs Through Orifice-Based Aerosolization
João Fernandes

Benchmarking Gravimetric FSI vs ACI: Can We Expedite Aerodynamic Performance Evaluation for Composite Powders?
Isabel Lopes

Aerodynamic Performance of DPIs: Predicting the Impact of Carrier-Based Formulation Parameters
Filipa Maia

API Influence & Stability Assessment of Spray Dried Composite Particles
Cláudia Moura

Optimizing Trade-Offs Between Product Performance and Process Efficiency via Powder Rheology
Maria Palha

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025